Semaglutide (Ozempic and Wegovy) is a once-weekly GLP-1 receptor agonist that mimics the gut hormone GLP-1 to suppress appetite, slow gastric emptying, and improve insulin response. Ozempic is approved for type 2 diabetes; Wegovy is approved for weight management at the higher 2.4 mg dose. The STEP-1 trial showed 14.9 percent average weight loss. Both are now available in India by prescription.
The DermaVue Clinics medical team prescribes semaglutide (Ozempic and Wegovy) for South Asian patients within a structured weight management protocol that includes weekly dose titration from 0.25 mg to 2.4 mg, monthly metabolic and renal review, and a 1.2 to 1.6 g/kg protein target to preserve lean mass. Across 7 physician-led DermaVue centres in Kerala and Tamil Nadu, the team has supported a patient base reflected in 7,200 plus reviews with a 4.8 average star rating. Pricing for semaglutide protocols starts at ₹5,660 per month and varies with brand and dose.
Understanding Semaglutide
What are Ozempic and Wegovy? Understanding Semaglutide
Ozempic and Wegovy are brand names for semaglutide, a GLP-1 receptor agonist manufactured by Novo Nordisk. Both medications contain the same active ingredient but are approved for different primary indications and at different doses. At DermaVue's board-certified physician clinics across Kerala and Tamil Nadu, semaglutide is prescribed as part of our full SuperHuman weight loss program with built-in dermatological monitoring.
| Feature | Ozempic | Wegovy |
|---|---|---|
| Generic Name | Semaglutide | Semaglutide |
| Primary Approval | Type 2 Diabetes | Chronic Weight Management |
| Max Dose | 2.0 mg weekly | 2.4 mg weekly |
| Administration | Weekly subcutaneous injection | Weekly subcutaneous injection |
Osenpick, Ozentic, Ozampic, Wegovy, Wygovy, Ozampik. All refer to semaglutide-based medications.
Mechanism of Action
How Does Semaglutide Injection Work?
Semaglutide mimics the GLP-1 hormone, acting on five key systems to reduce weight. Here is exactly what happens inside your body after each weekly injection.
| Target | What Semaglutide Does | What You Feel |
|---|---|---|
| Brain (Hypothalamus) | Hunger signals reduced | Eat less without willpower |
| Stomach | Gastric emptying slows | Full longer after meals |
| Liver | Glucagon production reduced | Less sugar released into blood |
| Pancreas | Insulin secretion improved | Better blood sugar control |
| Fat Cells | Visceral fat targeted | Belly fat reduction |
This multi-target mechanism is what makes semaglutide fundamentally different from older diet pills. It addresses the biological drivers of overeating. Not just willpower. Patients notice reduced food noise, fewer cravings, and genuine satiety within the first 2-3 weeks of treatment.
Head-to-Head Comparison
Ozempic vs Wegovy: Which is Right for You?
Both contain semaglutide but are prescribed differently. Here is a clinical comparison to help you and your doctor decide.
| Parameter | Ozempic | Wegovy |
|---|---|---|
| Active Ingredient | Semaglutide | Semaglutide |
| FDA Approval | Type 2 Diabetes (2017) | Chronic Weight Management (2021) |
| Starting Dose | 0.25 mg weekly | 0.25 mg weekly |
| Maintenance Dose | 0.5 - 2.0 mg weekly | 2.4 mg weekly |
| Weight Loss Focus | Secondary benefit | Primary indication |
| Diabetes Benefit | Primary indication | Secondary benefit |
| India Availability | Widely available | Limited availability |
India Market Update 2026
Generic Semaglutide in India 2026
Following patent expiry, multiple Indian pharmaceutical companies have launched generic semaglutide injections. This has made GLP-1 therapy significantly more accessible and affordable for Indian patients.
Dr. Reddy's (Obeda), Sun Pharma, and other CDSCO-approved manufacturers now offer semaglutide at a fraction of the branded price. Generic semaglutide starts at approximately ₹5,660/month.
Multiple Indian pharmaceutical companies including Dr. Reddy's (Obeda) and Sun Pharma are launching generic semaglutide. As more generics enter the market, prices are expected to decrease further. We will update our pricing as new options become CDSCO-approved.
DermaVue does not sell medications directly. After your clinical evaluation, your doctor will provide a prescription and advise on the most appropriate formulation based on quality, dosing, and your specific clinical needs. Medications are purchased from licensed pharmacies.
Not all generic semaglutide products are equivalent. Your DermaVue doctor evaluates manufacturer quality, cold-chain compliance, and bioequivalence data before recommending any specific brand. Never purchase semaglutide without a doctor's prescription.
Evidence-Based Medicine
STEP Clinical Trial Results
Semaglutide is one of the most studied weight-loss medications in history. Here are the key results from landmark trials that established its clinical credibility.
Semaglutide 2.4 mg achieved 14.9% mean body weight reduction vs 2.4% with placebo at 68 weeks. One-third of participants lost more than 20% of their body weight. This was the trial that established semaglutide as a serious weight-loss medication. [Wilding STEP 1, NEJM 2021]
In adults with type 2 diabetes and overweight or obesity, semaglutide 2.4 mg produced a 9.6 percent mean weight reduction at 68 weeks, with concurrent HbA1c improvement. Confirmation that the molecule works in the metabolically harder T2D population. [Davies STEP 2, Lancet 2021]
Semaglutide combined with intensive behavioural therapy and a low calorie diet produced a 16.0 percent mean weight loss at 68 weeks. The headline lesson: medication plus structured lifestyle support outperforms either alone. [Wadden STEP 3, JAMA 2021]
Long-term data: patients maintained an average 15.2% weight loss over 2 years of continuous semaglutide use, with sustained metabolic improvements including reduced HbA1c, blood pressure, and waist circumference.
In patients with established cardiovascular disease and obesity, but without diabetes, semaglutide reduced major adverse cardiovascular events by 20 percent. The trial moved semaglutide from a weight loss tool into a recognised cardiovascular risk reduction therapy. [Lincoff SELECT, NEJM 2023]
In adults with type 2 diabetes and chronic kidney disease, semaglutide reduced kidney disease progression by 24 percent. The implication for South Asian patients, where diabetic kidney disease is endemic, is direct. [Perkovic FLOW, NEJM 2024]
After stopping semaglutide, participants regained approximately two-thirds of lost weight within one year. This underscores why DermaVue's structured program includes a gradual tapering protocol and metabolic maintenance phase.
Dose Titration Protocol
Dosing Schedule & Titration
DermaVue follows a 5-step titration protocol to minimise side effects and optimise your response to semaglutide. You'll never be pushed to a higher dose before your body is ready.
| Period | Weekly Dose | Purpose |
|---|---|---|
| Weeks 1-4 | 0.25 mg | Initiation. Body adjustment |
| Weeks 5-8 | 0.5 mg | Early dose escalation |
| Weeks 9-12 | 1.0 mg | Therapeutic level. Appetite suppression begins |
| Weeks 13-16 | 1.7 mg | Advanced titration |
| Week 17+ | 2.0-2.4 mg | Full maintenance dose |
Dose escalation at DermaVue is always physician-guided. If you experience significant GI side effects at any stage, your doctor may extend that dose period by 2-4 weeks before proceeding. There is no "one size fits all" approach. Your titration is personalised to your tolerance.
Safety & Tolerability
Side Effects and How to Manage Them
Most side effects are gastrointestinal, mild to moderate in severity, and resolve within 4-8 weeks of continued use. Slow dose titration at DermaVue significantly reduces the frequency and severity of these effects.
| Side Effect | Frequency | DermaVue Management |
|---|---|---|
| Nausea | ~44% | Slow titration, smaller meals, avoid fatty foods, ondansetron if severe |
| Vomiting | ~24% | Anti-emetics as needed, hydration support, dose hold if persistent |
| Constipation | ~24% | Fibre supplementation, hydration, stool softeners if indicated |
| Diarrhoea | ~30% | Dietary adjustment, electrolyte monitoring, usually self-limiting |
Side effects usually resolve within 4-8 weeks. DermaVue's 5-step dose titration protocol is specifically designed to minimise gastrointestinal side effects during the adjustment period.
Important Safety Information
Who Should Not Take Semaglutide?
Semaglutide is not appropriate for everyone. A thorough medical evaluation is mandatory before any prescription. The following are absolute and relative contraindications.
Personal or family history of medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), history of pancreatitis, pregnancy or breastfeeding, known hypersensitivity to semaglutide or any excipient.
Severe renal impairment (eGFR below 30), diabetic retinopathy, severe gastroparesis, history of gallbladder disease, concurrent use of insulin or sulfonylureas (hypoglycaemia risk). These require specialist assessment and may need dose adjustment.
At DermaVue, every patient undergoes a full metabolic evaluation including thyroid function, kidney function, liver panel, and HbA1c before semaglutide is prescribed. This is not a medication you should ever start without medical supervision.
Dermatologist-Led Advantage
The Face-Saver Protocol: Preventing Ozempic Face at DermaVue
"Ozempic Face" refers to the gaunt, aged facial appearance caused by rapid facial fat loss during GLP-1 therapy. Volume loss in the cheeks, temples, and under-eyes can make patients look older even as their body gets leaner. This is the number one cosmetic concern with semaglutide treatment.
The face has a small number of discrete fat pads that sit at predictable anatomic positions. The deep medial cheek fat pad, the buccal fat pad, the lateral temporal fat compartment, and the nasolabial fat pad together create the youthful mid-face curve. These pads are highly metabolically active. When the body enters a sustained calorie deficit on a GLP-1 receptor agonist, fat is mobilised from every depot in proportion, and the face is no exception. A patient who loses 15 to 20 percent of body weight will lose roughly the same proportion from the facial fat pads. Because the face has so little to spare, the change is visible early.
The second mechanism is dermal. Rapid weight loss outpaces the skin's ability to retract. Collagen synthesis in adult skin is slow, elastin almost does not regenerate at all, and as the underlying volume drops, the dermis loses its scaffold and laxity becomes obvious at the jawline, temples, and under-eye region. Patients in their forties and fifties feel this most because baseline collagen density is already lower. Sun exposure in Kerala and Coimbatore accelerates the underlying photoageing and stacks on top of the volume loss.
The DermaVue cascade addresses both problems in sequence. Profhilo restores deep dermal hydration and stimulates collagen and elastin through hyaluronic acid bio-remodelling. Sculptra, a poly-L-lactic acid biostimulator, drives gradual neocollagenesis across the mid-face over several months. Hyaluronic acid mid-face fillers replace lost volume directly at the deep medial cheek and zygomatic positions. Morpheus8 radiofrequency microneedling tightens the dermis through controlled thermal energy delivered into the deeper layers of the skin. Polynucleotide biostimulators (PDRN) regenerate dermal tissue and improve skin quality in patients who need a softer, lower volume approach. The choice and order is individualised by the dermatologist after examination. Most patients receive a layered combination, not a single treatment.
Timing note. Start aesthetic interventions at week 12 to 16 of GLP-1 therapy, once weight loss has stabilised. Treating earlier risks chasing a moving target, and treating later means you spend months looking older than you should. This is the DermaVue clinical protocol developed across several thousand GLP-1 patients.
DermaVue Face-Saver Protocol
Month 1. Oral Collagen + Retinol
Collagen peptide supplementation to support dermal matrix, medical-grade retinol to stimulate fibroblast activity and maintain skin thickness.
Month 2. Profhilo Bio-Remodeling
Injectable hyaluronic acid bio-remodeling to restore deep hydration and stimulate collagen and elastin production across the mid-face.
Month 3. Polynucleotides (PDRN)
Polydeoxyribonucleotide injections to regenerate skin tissue, improve elasticity, and counteract the volume-loss effects of rapid weight reduction.
Month 6+. MFU-V / Ultherapy (if indicated)
Micro-focused ultrasound with visualisation for non-surgical lifting and tightening of lax skin, assessed on a case-by-case basis.
No other weight loss clinic in Kerala provides built-in dermatological protection against Ozempic Face. Because DermaVue is a dermatology clinic first, we proactively protect your skin and face while you lose weight.
Honest Comparison
Semaglutide vs Tirzepatide: Honest Comparison
At DermaVue, Mounjaro (tirzepatide) is our preferred first-line medication for most patients due to superior clinical outcomes. Ozempic/semaglutide is recommended for patients with specific clinical indications, budget considerations, or thin-fat phenotype without high insulin resistance.
| Parameter | Semaglutide (Ozempic/Wegovy) | Tirzepatide (Mounjaro) |
|---|---|---|
| Mechanism | GLP-1 receptor agonist (single) | Dual GIP + GLP-1 receptor agonist |
| Weight Loss % | ~14.9% (STEP 1) | ~22.5% (SURMOUNT-1) |
| SURMOUNT-5 Head-to-Head | 13.7% body weight reduction | 20.2% body weight reduction |
| India Availability | Widely available (branded + generic) | Available |
| DermaVue Recommendation | Specific clinical indications, budget-conscious, thin-fat phenotype | First-line for most patients |
Your Protocol at DermaVue
How We Prescribe Semaglutide at DermaVue
Every semaglutide prescription at DermaVue follows a structured, physician-supervised protocol. You'll never be handed a pen and left to figure it out alone.
Metabolic Evaluation
Full blood work: thyroid function, HbA1c, lipid panel, kidney function, liver enzymes. Body composition analysis via DEXA or bioimpedance. BMI + waist-hip ratio assessment.
Physician Consultation
Face-to-face or video consultation with your DermaVue physician. Review of results, contraindication screening, goal setting, and medication selection (semaglutide vs tirzepatide).
Personalised Protocol
Your doctor creates a custom titration schedule, diet plan, exercise protocol, and skin protection timeline (Face-Saver Protocol).
Monthly Monitoring
Monthly check-ins track weight, body composition, metabolic markers, and skin health. Dose adjustments are made based on your response and tolerance.
Maintenance & Tapering
When you reach your target weight, we begin a gradual tapering protocol with metabolic maintenance strategies to prevent the weight regain seen in clinical trials.
DermaVue is a physician-owned dermatology and metabolic health clinic network with 7 locations across Kerala and Tamil Nadu, India. The SuperHuman program provides doctor-supervised semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro) therapy for chronic weight management. Founded by US and India trained physicians Dr. Sarath Chandran MD DVL and Dr. Rejeesh M. Menon MD, DermaVue uniquely combines GLP-1 medical weight loss with dermatological skin protection through its proprietary Face-Saver Protocol. The clinic network maintains a 4.8-star average rating across 7,281 Google reviews. Semaglutide 0.25mg starting dose begins at approximately ₹5,660/month with mandatory physician evaluation.
Source: DermaVue Clinical Knowledge Base, reviewed April 2026Generic GLP-1 Update. March 2026
Generic semaglutide entered the Indian market in March 2026. Branded Ozempic at 0.5 mg weekly previously ran around Rs 8,100 per month. Indian generics from Natco, Alkem, and Dr. Reddy's now sit between Rs 1,290 and Rs 4,200 at the same dose. The molecule and safety profile are identical. Physician supervision is still required because GLP-1 therapy carries real contraindications. Cheaper does not mean safer to self-prescribe.
68 weeks both arms
STEP 1 (NEJM 2021) vs STEP 2 (Lancet 2021).
+6.5pp absolute difference
First open-label head-to-head between single and dual receptor agonists.
Generic India strengths: 0.25 / 0.5 / 1 mg
Both weekly subcutaneous, manufactured by Novo Nordisk.
Medically reviewed by Dr. Rejeesh Menon, MD · Medical Director, SuperHuman Program · Last reviewed 5 April 2026
Ozempic & Wegovy FAQ
Doctor-verified answers to the most common questions about semaglutide for weight loss in India.
What is Ozempic and how is it different from Wegovy?
Both Ozempic and Wegovy contain the same active ingredient. Semaglutide. Ozempic is FDA-approved for type 2 diabetes at doses up to 2.0mg weekly, while Wegovy is specifically approved for chronic weight management at the higher 2.4mg dose. Both are manufactured by Novo Nordisk.
How does semaglutide work for weight loss?
Semaglutide mimics the GLP-1 hormone. It reduces appetite by acting on hunger centres in the brain, slows stomach emptying so you feel full longer, improves insulin secretion, reduces glucagon production, and helps target visceral (belly) fat. Clinical trials show average weight loss of 14.9% over 68 weeks.
How long do I need to take Ozempic or Wegovy?
Treatment is typically prescribed for 12-18 months as part of a structured program. The exact duration depends on your starting weight, target weight, metabolic health markers, and response to treatment. Stopping should always be gradual and doctor-supervised to prevent weight regain.
What are the most common side effects?
The most common side effects are gastrointestinal. Nausea (44%), diarrhoea (30%), vomiting (24%), and constipation (24%). These are usually mild to moderate and typically resolve within 4-8 weeks. DermaVue's slow 5-step dose titration significantly reduces the severity of these effects.
Is generic semaglutide available in India?
Yes, generic semaglutide injections are available in India from several licensed manufacturers following patent expiry in 2026. Your DermaVue doctor will advise on the most appropriate option based on quality and your clinical needs.
Is Ozempic better than Mounjaro (tirzepatide) for weight loss?
Head-to-head clinical data from the SURMOUNT-5 trial shows tirzepatide (Mounjaro) achieves greater weight loss. 20.2% vs 13.7% body weight reduction. DermaVue recommends Mounjaro as first-line for most patients, with semaglutide reserved for those with specific clinical indications, budget constraints, or thin-fat phenotype without significant insulin resistance.
Where can I get semaglutide in India?
Semaglutide is available at licensed pharmacies across India in both branded (Ozempic, Wegovy) and generic formulations. A doctor's prescription is mandatory. Your DermaVue doctor will advise on the appropriate brand based on quality, dosing requirements, and your clinical profile.
Who should NOT take semaglutide?
Semaglutide is contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), history of pancreatitis, pregnancy or breastfeeding, and severe gastrointestinal disorders such as gastroparesis. A full medical evaluation at DermaVue is mandatory before any prescription.
What is Ozempic Face and how does DermaVue prevent it?
Ozempic Face is the gaunt, aged facial appearance caused by rapid facial fat loss during GLP-1 therapy. DermaVue prevents it with a Face-Saver Protocol: oral collagen + retinol (Month 1), Profhilo bio-remodeling (Month 2), polynucleotide injections (Month 3), and MFU-V/Ultherapy if needed (Month 6+). No other weight loss clinic in Kerala provides built-in dermatological protection.
How much does semaglutide cost in India?
Semaglutide treatment starts at approximately ₹5,660 per month. Your doctor will discuss dosing and pricing during your consultation. Generic GLP-1 medications are entering the Indian market. Pricing will be updated as new options become available. DermaVue does not sell medications directly. Prescriptions are provided after clinical evaluation and medications are purchased from licensed pharmacies.
Why are there so many spellings of Wegovy and Ozempic?
Wegovy and Ozempic are global brand names from Novo Nordisk, but Indian patients often hear them spoken in clinics, pharmacies, and reels and then type them phonetically. That produces searches like Wygobi, Vigovi, Wagobi, Weg Ovy, Ozentic, and Osenpick. They all refer to the same molecule, semaglutide. The clinical care and prescription protocol stays the same regardless of how the brand is spelled.
Visit Any of Our 7 Clinics
Or book a teleconsultation from anywhere in India
DermaVue SuperHuman Program
Ready to Start Semaglutide Therapy?
Talk to a doctor. Free 10-minute WhatsApp consultation to discuss whether Ozempic, Wegovy, or Mounjaro is right for you.
4.8 rating · 7,200+ patients · Dermatologist-led program · 7 clinics